-- Shanghai Henlius Biotech (HKG:2696) obtained approval for a phase 1 clinical trial of HLX05-N from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The drug is being studied for the treatment of metastatic colorectal cancer.